EPElsa Pennese

Elsa Pennese

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elsa Pennese has a total of 178 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Optimizing Frontline Targeted Therapies in Chronic Lymphocytic Leukemia: An Italian Inter‐Regional Delphi Consensus on Patient Risk Stratification, Cardiovascular Safety, and Endpoint Interpretation

    by Stefano Molica, Giacomo Loseto, Elsa Pennese, Francesco Aji, Angelo Fama, Annamaria Giordano, Giulio Giordano, Francesca Immacolata Merchionne, Rosanna Maria Miccolis, Gaetano Palumbo, et al.

    Background: While landmark trial data have established targeted agents as the frontline standard of care in chronic lymphocytic leukemia (CLL), real‐world clinical gaps remain regarding high‐risk disease biology, patient frailty, cardiovascular comorbidities, healthcare accessibility, and the clinical interpretation of surrogate endpoints. Methods: A modified two‐round Delphi process engaged an expert panel of 19 Italian hematology specialists and a multidisciplinary scientific board to evaluate 16 evidence‐based statements across four key clinical domains. Statements were formulated based on literature evidence‐informed from a systematic review of the literature. When high‐tier evidence was lacking, statements used lower‐level data and expert consensus to address clinical gaps. Consensus was pre‐defined as an aggregate agreement of 70% using a forced‐choice 4‐point Likert scale. Results: Continuous monotherapy with second‐generation covalent BTK inhibitors (cBTKis) was preferred over time‐limited regimens for patients with TP53‐disrupted disease (94.6%), individuals aged > 80 years or meeting frailty criteria (100%), and those with socio‐logistic or caregiver constraints (95.0%). Conversely, time‐limited regimens were universally favored for fit patients aged < 70 years without TP53 aberrations (100%), while remaining a viable option in young, fit patients with TP53 disruptions (78.9%). Baseline cardiovascular risk stratification using population‐validated tools (SCORE2, SCORE2‐OP, SCORE2‐Diabetes) reached 85.0% agreement. Second‐generation cBTKis were preferred over ibrutinib in patients with elevated cardiovascular risk (95.0%). Panelists agreed that undetectable measurable residual disease (uMRD) is not a universal surrogate for progression‐free survival (70.0%). Time to next treatment (TTNT) was unanimously endorsed as an efficacy indicator for time‐limited therapy (100%), but viewed primarily as a safety surrogate during continuous cBTKi therapy (79.0%). Upon relapse after time‐limited cBTKi–venetoclax therapy, re‐challenge with a covalent BTKi was established as the preferred option (89.5%). Conclusion: This consensus bridges clinical guidelines and real‐world practice, providing a structured framework that incorporates molecular risk, functional frailty, cardiovascular scoring, and healthcare accessibility to guide frontline CLL management.

  • Open Access

    Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study

    by Stefano Luminari, Maria Elena Nizzoli, Michele Merli, Sara Rattotti, Vittoria Tarantino, Simone Ferrero, Annalisa Talami, Roberta Murru, Marina Deodato, Emanuele Cencini, et al.

    Summary: While marginal zone lymphoma (MZL) is generally indolent, outcomes following relapse remain poorly defined. This study utilized the indolent Non Follicular 10 (NF10) prospective database to characterize survival and identify prognostic drivers in patients failing initial systemic therapy. The study analysed 122 patients with relapsed MZL. The primary end‐point was progression‐free survival from first relapse (2PFS), with survival after relapse (SAR) as the secondary end‐point. The median 2PFS was 24 months, with a 2‐year 2PFS rate of 49% and a 2‐year SAR rate of 66%. Multivariable analysis identified advanced age, progression of disease within 24 months (POD24) and high MZL International Prognostic Index (MZL‐IPI) scores as significant predictors of inferior survival. Patients with splenic and disseminated subtypes also demonstrated worse outcomes. Relapse following systemic therapy often marks a transition to an aggressive clinical course. Time to progression and the MZL‐IPI are robust tools for risk stratification, highlighting an urgent need for novel therapeutic strategies for high‐risk relapsed MZL populations.

  • Long‐Term Clinical Outcomes, Adherence, Persistence, and Adverse Event Management in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib

    by Santoleri Fiorenzo, Pennese Elsa, Sanna Alessandro, Pittorru Mario, Tonialini Lorenzo, De Bello Federica, Scortechini Ilaria, Guglielmi Sabrina, Ranucci Elena, Schiattone Luana, et al.

    Background: Long‐term treatment with Bruton's tyrosine kinase inhibitors has substantially improved outcomes in chronic lymphocytic leukemia (CLL). However, real‐world evidence simultaneously evaluating clinical outcomes, treatment adherence, persistence, and adverse event management remains limited. This study assessed long‐term treatment dynamics and clinical outcomes in patients with CLL receiving ibrutinib in routine clinical practice. Methods: We conducted a multicenter, retrospective, observational study involving four Italian centers. Adult patients with CLL treated with ibrutinib between January 2016 and June 2024 were included. Clinical records were linked with hospital pharmacy dispensing registries to evaluate progression‐free survival (PFS), overall survival (OS), time to treatment discontinuation (TTD), adherence, persistence, and adverse event management. Adherence was calculated using dispensing data adjusted according to the prescribed daily dose (PDD). Kaplan–Meier analyses were performed for survival outcomes, while multivariable logistic and Cox regression models were used to identify factors associated with adherence and clinical outcomes. Results: A total of 276 patients were included (47% first‐line, 36% second‐line, and 17% third‐line or later therapy). Mean age was 70 ± 10 years and 63% were male. Adherence remained consistently high across treatment lines and throughout follow‐up, with mean adherence values generally ranging between 0.75 and 0.90. At 8 years, first‐line patients achieved PFS, OS, and TTD rates of 86.4%, 64.5%, and 61.4%, respectively. Corresponding estimates were 72.7%, 49.5%, and 23.1% in second‐line patients and 95.8%, 49.4%, and 53.5% among patients receiving third‐line or later therapy. Adverse drug reactions occurred in 53% of patients; 74% resolved following clinical management. Higher comorbidity burden (CIRS > 6) was independently associated with optimal adherence (OR 2.12, 95% CI 1.12–4.00; p = 0.016) and lower risk of treatment discontinuation (HR 0.36, 95% CI 0.16–0.80; p = 0.013). Conclusions: Long‐term treatment with ibrutinib was associated with favorable clinical outcomes, sustained adherence, and prolonged treatment persistence in routine clinical practice. Proactive adverse event management and individualized treatment optimization may contribute substantially to maintaining long‐term treatment exposure and maximizing clinical benefit.

  • Open Access

    CAR-T TEMRA and CAR-Tregs in vivo expansion are both associated with a poor response after CD19.CAR-T therapy

    by Luigi Carriero, Lucia Di Re, Francesco Guardalupi, Raffaella Giancola, Fabrizia Colasante, Giulia Corradi, Francesca Troiano, Noemi Michetti, Giuseppina Ricciuti, Luana Schiattone, et al.

  • Open Access

    Real-world outcomes of tafasitamab-lenalidomide in patients with transplant-ineligible R/R DLBCL from the PRO-MIND study

    by Pier Luigi Zinzani, Maria Cristina Cox, Flaminia Bellisario, Andrea Bernardelli, Maurizio Musso, Guido Gini, Alice Di Rocco, Eliana Valentina Liardo, Enrico Derenzini, Elsa Pennese, et al.

  • Open Access

    Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study

    by Luca Arcaini, Michele Merli, Sara Rattotti, Maria Elena Nizzoli, Vittoria Tarantino, Chiara Consoli, Annalisa Talami, Roberta Murru, Marina Deodato, Emanuele Cencini, et al.


  • Open Access

    Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort

    by Enrica Antonia Martino, Annalisa Pitino, Ernesto Vigna, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Andrea Visentin, Alessandro Sanna, Marina Motta, Massimo Moratti, et al.

    Bruton tyrosine kinase inhibitors (BTKis) have dramatically changed the therapeutic landscape of chronic lymphocytic leukemia (CLL), with ibrutinib, first-in-class, demonstrating durable efficacy even in high-risk patients. However, off-target adverse events (AEs) have raised concerns, prompting the development of more selective second-generation BTKis, such as zanubrutinib, designed to improve tolerability while maintaining efficacy. Despite encouraging results from clinical trials, real-world data comparing zanubrutinib with ibrutinib remain limited. In this multicenter, retrospective study, we analyzed 934 patients with CLL treated outside clinical trials, including 393 receiving zanubrutinib and 541 receiving ibrutinib. We evaluated time to treatment discontinuation (TTD) and time to next treatment or death (TTNTD) in both the overall cohort and a propensity score–matched population. Patients who were treated with zanubrutinib experienced lower 12-month discontinuation rates (overall: 12.6% vs 21.4%; matched: 12.4% vs 20.2%) and higher 12-month TTNTD rates (overall: 91.9% vs 83.0%; matched: 93.2% vs 83.4%). Multivariable analyses confirmed zanubrutinib as an independent predictor of longer TTD and TTNTD, whereas high-risk features, including age, relapsed/refractory disease, Binet stage C, TP53 disruption, Eastern Cooperative Oncology Group 2 to 3, and congestive heart failure, were consistently associated with poorer outcomes. AEs leading to discontinuation, particularly atrial fibrillation, bleeding, and infections, were less frequent with zanubrutinib, reflecting its favorable safety profile. These findings provide real-world evidence that zanubrutinib offers more durable disease control and improved persistence compared with ibrutinib, reinforcing its clinical value as a preferred second-generation BTKi. Nevertheless, the relatively short follow-up for zanubrutinib warrants cautious interpretation of long-term outcomes, and underscores the need for ongoing observation to fully characterize its durability and safety.